Wedlund P J, Aslanian W S, McAllister C B, Wilkinson G R, Branch R A
Clin Pharmacol Ther. 1984 Dec;36(6):773-80. doi: 10.1038/clpt.1984.256.
The ability of normal subjects to hydroxylate mephenytoin (100 mg) or debrisoquine (10 mg) after oral dosing was investigated in 156 unrelated Caucasians living in middle Tennessee. Urinary recovery of 4-hydroxymephenytoin (4-OH-M) and the urinary S:R enantiomeric ratio of mephenytoin measured in an 8-hr urine sample were investigated as phenotypic traits for mephenytoin, and the urinary metabolic ratio of debrisoquine was used to determine the debrisoquine hydroxylase phenotype. Both urinary 4-OH-M and the S:R ratio of mephenytoin discriminated between extensive (EM) and poor (PM) metabolizers of mephenytoin. The frequencies of PMs for mephenytoin and debrisoquine hydroxylation activity were 2.6% and 7.0%. These two defects in oxidative metabolism were not observed in the same subjects, which suggests that 4-hydroxylation of mephenytoin is a new polymorphism independent of that for debrisoquine.
对居住在田纳西州中部的156名无亲缘关系的高加索人进行了研究,以考察正常受试者口服给药后对美芬妥英(100毫克)或异喹胍(10毫克)的羟化能力。测定了8小时尿液样本中4-羟基美芬妥英(4-OH-M)的尿回收率和美芬妥英的尿S:R对映体比率,作为美芬妥英的表型特征,并使用异喹胍的尿代谢比率来确定异喹胍羟化酶表型。尿4-OH-M和美芬妥英的S:R比率均能区分美芬妥英的快代谢型(EM)和慢代谢型(PM)。美芬妥英和异喹胍羟化活性的PM频率分别为2.6%和7.0%。在同一受试者中未观察到这两种氧化代谢缺陷,这表明美芬妥英的4-羟化是一种独立于异喹胍的新多态性。